SMTL ID : 8bsn.1

Human GLS in complex with compound 27

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.49 Å

Oligo State

homo-tetramer

Ligands

20 x SO4: SULFATE ION(Non-functional Binders)

SO4.1: 3 residues within 4Å: Chain A: V.116, N.117, R.169 Ligand excluded by PLIP SO4.2: 4 residues within 4Å: Chain A: F.155, S.156, N.157, A.158 Ligand excluded by PLIP SO4.3: 4 residues within 4Å: Chain A: Y.176, K.180 Chain B: K.102, R.169 Ligand excluded by PLIP SO4.4: 3 residues within 4Å: Chain A: F.160, Q.161, R.164 Ligand excluded by PLIP SO4.5: 3 residues within 4Å: Chain A: Y.90, P.184, E.185 Ligand excluded by PLIP SO4.7: 3 residues within 4Å: Chain B: V.116, N.117, R.169 Ligand excluded by PLIP SO4.8: 4 residues within 4Å: Chain B: F.155, S.156, N.157, A.158 Ligand excluded by PLIP SO4.9: 4 residues within 4Å: Chain A: K.102, R.169 Chain B: Y.176, K.180 Ligand excluded by PLIP SO4.10: 3 residues within 4Å: Chain B: F.160, Q.161, R.164 Ligand excluded by PLIP SO4.11: 3 residues within 4Å: Chain B: Y.90, P.184, E.185 Ligand excluded by PLIP SO4.13: 3 residues within 4Å: Chain C: V.116, N.117, R.169 Ligand excluded by PLIP SO4.14: 4 residues within 4Å: Chain C: F.155, S.156, N.157, A.158 Ligand excluded by PLIP SO4.15: 4 residues within 4Å: Chain C: Y.176, K.180 Chain D: K.102, R.169 Ligand excluded by PLIP SO4.16: 3 residues within 4Å: Chain C: F.160, Q.161, R.164 Ligand excluded by PLIP SO4.17: 3 residues within 4Å: Chain C: Y.90, P.184, E.185 Ligand excluded by PLIP SO4.19: 3 residues within 4Å: Chain D: V.116, N.117, R.169 Ligand excluded by PLIP SO4.20: 4 residues within 4Å: Chain D: F.155, S.156, N.157, A.158 Ligand excluded by PLIP SO4.21: 4 residues within 4Å: Chain C: K.102, R.169 Chain D: Y.176, K.180 Ligand excluded by PLIP SO4.22: 3 residues within 4Å: Chain D: F.160, Q.161, R.164 Ligand excluded by PLIP SO4.23: 3 residues within 4Å: Chain D: Y.90, P.184, E.185 Ligand excluded by PLIP

4 x R0C: (2~{S})-2-methoxy-2-phenyl-~{N}-[5-[[(3~{R})-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]ethanamide(Non-covalent)

R0C.6: 13 residues within 4Å: Chain A: K.102, L.103, F.104, L.105, Y.176 Chain B: K.102, L.103, F.104, L.105, N.106, E.107, Y.176 Ligands: R0C.12 10 PLIP interactions: 5 interactions with chain A, 5 interactions with chain B Hydrophobic interactions: A:F.104, B:K.102, B:L.103 Hydrogen bonds: A:K.102, A:K.102, A:F.104, A:L.105, B:F.104, B:L.105, B:L.105 R0C.12: 13 residues within 4Å: Chain A: K.102, L.103, F.104, L.105, N.106, E.107, Y.176 Chain B: K.102, L.103, F.104, L.105, Y.176 Ligands: R0C.6 11 PLIP interactions: 5 interactions with chain A, 6 interactions with chain B Hydrophobic interactions: A:K.102, A:L.103, B:F.104 Hydrogen bonds: A:F.104, A:L.105, A:L.105, B:K.102, B:K.102, B:F.104, B:L.105, B:Y.176 R0C.18: 13 residues within 4Å: Chain C: K.102, L.103, F.104, L.105, Y.176 Chain D: K.102, L.103, F.104, L.105, N.106, E.107, Y.176 Ligands: R0C.24 10 PLIP interactions: 5 interactions with chain C, 5 interactions with chain D Hydrophobic interactions: C:F.104, D:K.102, D:L.103 Hydrogen bonds: C:K.102, C:K.102, C:F.104, C:L.105, D:F.104, D:L.105, D:L.105 R0C.24: 13 residues within 4Å: Chain C: K.102, L.103, F.104, L.105, N.106, E.107, Y.176 Chain D: K.102, L.103, F.104, L.105, Y.176 Ligands: R0C.18 11 PLIP interactions: 5 interactions with chain C, 6 interactions with chain D Hydrophobic interactions: C:K.102, C:L.103, D:F.104 Hydrogen bonds: C:F.104, C:L.105, C:L.105, D:K.102, D:K.102, D:F.104, D:L.105, D:Y.176

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Finlay, M.R.V. et al., Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models. J Med Chem (2019)

Release Date

2023-01-18

Peptides

Glutaminase kidney isoform, mitochondrial 65 kDa chain: ABCD

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
A

C
A

D
A

Glutaminase kidney isoform, mitochondrial 65 kDa chain

Related Entries With Identical Sequence